Abstract:Background Hepatitis B is a highly prevalent disease. About 257 million people are infected with hepatitis B virus (HBV), and more than 887 000 annual new acute or chronic cases of hepatitis B are recorded globally. HBV infection is also highly prevalent in China, where around 60 million people are positive for HBV antigens, and about 20 million people have chronic HBV infection. The Chinese government launched the national hepatitis B immunisation programme in 2002 that provides vaccination free of charge. Our study aimed to establish the effects of neonatal hepatitis B vaccine in China. Methods For our analysis, we obtained data on HBV infection cases from the China Epidemic Data Collection System and the China Public Health science data centre; data on costs related to HBV infection were acquired from a survey of the Evaluation Project of the National Immunisation Programme of China. We used a mathematical model and a decision tree-Markov model in this modelling study. In the mathematical model, nine compartments were expanded from a typical susceptible-exposed-infected-recovered model. In the decision tree-Markov model, eight Markov states were included to simulate hepatitis B virus infection and progression. We compared various intervention scenarios to establish the effects and cost-effectiveness of hepatitis B vaccination through the primary outcome of the study, incidence of HBV infection cases, which could provide evidence for exploring new prevention and control strategies. Findings Our study estimated the number of chronic HBV infection cases from 1998 to 2018, and projected the prevalence of the epidemic in the following 30 years. Since the expanded immunisation plan began in 2008, the number of new acute hepatitis B cases decreased by 56·02% in 2018. Comparing the first scenario (status quo) with the second scenario (without any prior intervention), the model estimated that new chronic HBV infection cases have reduced by 95·13%. In other words, about 20·97 million new chronic HBV infection cases were averted because of hepatitis B vaccination. The cost-effectiveness analysis showed that the implementation of the neonatal hepatitis B vaccine strategy could increase effectiveness by 1·77 quality-adjusted life years (QALY) per capita; and although each person obtained a unit of QALY, the cost for the whole of society was a saving of US$8142·29. Interpretation Our findings supported the effectiveness of HBV vaccination in controlling the epidemic of hepatitis B after about 20 years of implementation of the national hepatitis B immunisation programme. Although China has achieved a great deal in hepatitis B prevention, the burden of this disease remains quite heavy in China, especially in terms of mother-to-child transmission. Therefore, more strategies need to be explored for controlling and eventually eliminating hepatitis B. Funding Evaluation Project of the National Immunisation Programme of China.

Evaluation of Health Economics on the Different Regimens of Booster Immunization and Screening Scheme Before Hepatitis B Vaccination in Beijing

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

The Economic Evaluation of Hepatitis B Vaccine Interference in Haidian District of Beijing

Analysis on Cost-Benefit for Infant Hepatitis B Vaccine Immunization Strategy in Beijing

Economic Evaluatin of Heptatis B Vaccine Immunization in Haidian District,Beijing

Impact and cost-effectiveness of a national hepatitis B immunisation programme in China: a modelling study

Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period.

Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

Impact and Cost-Effectiveness of National Hepatitis B Immunization Program in China

[Decision tree and cost-benefit analysis on strategies related to preventing maternal-infantile transmission of hepatitis B virus infection]

Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: A decision-analytic Markov model

Immune Response to Hepatitis B Vaccine in Children Born to HBsAg Positive Mothers: a Meta-Regression Analysis

Impact of the national hepatitis B immunization program in China: a modeling study

Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049

Suitable hepatitis B vaccine for adult immunization in China: a systematic review and meta-analysis.

Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

A System Dynamics Modelling Simulation Based on a Cohort of Hepatitis B Epidemic Research in East China Community

Targeted Hepatitis E Vaccination for Women of Childbearing Age is Cost-Effective in China.

Post‐vaccination serologic testing of infants born to hepatitis B surface antigen‐positive mothers is more cost‐effective in Zhejiang Province, China: A Markov chain analysis

The One Year Effects of Three Doses of Hepatitis B Vaccine As a Booster in Anti-Hbs-negative Children 11–15 Years after Primary Immunization; China, 2009–2011